All In Biotech

Free tool

FAERS Monitor: Ctexli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219488 or its brand name (Ctexli, Chenodiol). Reports on generic versions are filed under their own applications.

Reports

32

Serious

17

53% of reports

Hospitalization

11

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dehydration5
  • off label use5
  • adenovirus infection4
  • anaphylactic shock4
  • drug ineffective4
  • ear infection4
  • gastroenteritis viral4
  • herpes zoster disseminated4
  • human bocavirus infection4
  • lymphopenia4
  • multiple organ dysfunction syndrome4
  • optic neuritis4
  • renal failure4
  • respiratory failure4
  • retinitis4

Reports by year received

View as table
YearReports
20101
20111
20141
20162
20172
20185
20192
20203
20222
20236
20241
20253
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
human bocavirus infectionSignal414225.85624.342,638
herpes zoster disseminatedSignal43293.81313.510,031
retinitisSignal41525.7609.34,655
adenovirus infectionSignal4907.8362.72,770
optic neuritisSignal4289.5115.7880
lymphopeniaSignal4186.074.3563
gastroenteritis viralSignal4145.758.2439
anaphylactic shockSignal4102.040.8306
ear infectionSignal498.839.5296
multiple organ dysfunction syndromeSignal492.837.1278
respiratory failureSignal436.114.4104
dehydrationSignal524.611.092
renal failureSignal419.87.954
off label useSignal53.81.78
drug ineffective42.00.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.